OPIANT PHARMACEUTICALS INC (OPNT) Stock Analyst Earnings Estimates
NASDAQ:OPNT - Nasdaq - US6837501039 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40.52M 189.84% | 29.63M -26.88% | 47.785M 61.27% | 9.18M -80.79% | 38.046M 314.44% | 78.183M 105.50% | |
| EBITDA YoY % growth | 10.97M 151.77% | -2.12M -119.33% | 5.251M 347.68% | N/A | N/A | N/A | |
| EBIT YoY % growth | 10.91M 151.49% | -2.24M -120.53% | 5.156M 330.19% | -42.432M -922.91% | -31.518M 25.72% | -21.318M 32.36% | |
| Operating Margin | 26.92% | -7.56% | 10.79% | -462.22% | -82.84% | -27.27% | |
| EPS YoY % growth | 2.04 157.47% | -0.46 -122.55% | 0.32 169.57% | -7.54 -2,455.56% | -3.40 54.87% | 1.49 143.78% |
All data in USD
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.23 -1,222.00% | -2.18 10.17% | -2.30 0.65% | 0.83 143.03% | 0.90 172.73% |
| Revenue Q2Q % growth | 1.836M -86.70% | 2.346M -47.52% | 2.04M -47.62% | 22.95M 13,099.52% | 26.826M 1,361.11% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.466M -764.52% | -10.914M 7.41% | -11.628M -2.31% | 7.14M 174.14% | 7.65M 190.36% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | -1.92 -442.86% | -1.52 | -0.40 | -26.05% |
| Q2 2022 Q2Q % growth | -2.31 -845.16% | -1.39 | -0.92 | -65.91% |
| Q1 2022 Q2Q % growth | -2.43 -268.18% | -0.93 | -1.50 | -162.52% |
| Q4 2021 Q2Q % growth | 0.11 168.75% | -0.01 | 0.12 | 1,178.43% |
| Q3 2021 Q2Q % growth | 0.56 273.33% | 0.22 | 0.34 | 157.36% |
| Q2 2021 Q2Q % growth | 0.31 720.00% | -0.29 | 0.60 | 208.54% |
| Q1 2021 Q2Q % growth | -0.66 -65.00% | -0.72 | 0.06 | 8.86% |
| Q4 2020 Q2Q % growth | -0.16 -180.00% | 0.07 | -0.23 | -313.91% |
| Q3 2020 Q2Q % growth | 0.15 -92.39% | -0.21 | 0.36 | 171.16% |
| Q2 2020 Q2Q % growth | -0.05 -116.13% | -0.25 | 0.20 | 79.85% |
| Q1 2020 Q2Q % growth | -0.40 9.09% | -0.20 | -0.20 | -102.84% |
| Q4 2019 Q2Q % growth | 0.20 | -2.17 | 2.37 | 109.21% |
| Q3 2019 Q2Q % growth | 1.97 | -0.09 | 2.06 | 2,328.42% |
| Q2 2019 Q2Q % growth | 0.31 | -0.56 | 0.87 | 154.93% |
| Q1 2019 Q2Q % growth | -0.44 | -0.81 | 0.37 | 45.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | 173.87K -98.94% | 3.757M | -3.583M | -95.37% |
| Q2 2022 Q2Q % growth | 3.894M -65.41% | 4.748M | -853.72K | -17.98% |
| Q1 2022 Q2Q % growth | 4.47M -30.05% | 6.018M | -1.548M | -25.72% |
| Q4 2021 Q2Q % growth | 13.8M 39.12% | 13.528M | 272.22K | 2.01% |
| Q3 2021 Q2Q % growth | 16.339M 79.35% | 12.373M | 3.966M | 32.05% |
| Q2 2021 Q2Q % growth | 11.259M 78.44% | 8.366M | 2.893M | 34.58% |
| Q1 2021 Q2Q % growth | 6.39M 49.30% | 5.396M | 994K | 18.42% |
| Q4 2020 Q2Q % growth | 9.92M 29.34% | 9.384M | 536K | 5.71% |
| Q3 2020 Q2Q % growth | 9.11M -55.86% | 7.913M | 1.197M | 15.13% |
| Q2 2020 Q2Q % growth | 6.31M -6.93% | 6.197M | 113K | 1.82% |
| Q1 2020 Q2Q % growth | 4.28M -21.32% | 4.947M | -667K | -13.48% |
| Q4 2019 Q2Q % growth | 7.67M | 7.785M | -115K | -1.48% |
| Q3 2019 Q2Q % growth | 20.64M | 5.627M | 15.013M | 266.80% |
| Q2 2019 Q2Q % growth | 6.78M | 4.087M | 2.693M | 65.89% |
| Q1 2019 Q2Q % growth | 5.44M | 3.009M | 2.431M | 80.79% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 40.78% | 40.78% | 8.77% | 0.18% |
| Revenue | 63.64% | 63.64% | -2.9% | -44.97% |